Decreased expression and altered methylation of syncytin-1 gene in human placentas associated with preeclampsia

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1796-1802

  Zhuang, Xue Wei ^a,b   Li, Jinping ^b,c   Brost, Brian C ^c   Xia, Xi Yan ^b,d   Chen, Hai Bin ^e   Wang, Chuan Xin ^a   Jiang, Shi Wen ^b,c,f  

^a SHANDONG UNIVERSITY   (China)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mayo Clinic   (United States)

^d Jinan nursing training college   (China)

^e SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^f MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA methylation; Placenta; Preeclampsia; Syncytin 1; Trophoblast

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; HUMAN PLACENTA LACTOGEN; MESSENGER RNA; PROTEIN; PROTEIN ASCT 2; SYNCYTIN 1; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; PLACENTA PROTEIN; SYNCYTIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL FUSION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTROPHOBLAST; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SYNCYTIOTROPHOBLAST; SYNCYTIUM; DOWN REGULATION; DRUG EFFECTS; ENDOGENOUS RETROVIRUS; GENETIC EPIGENESIS; GENETICS; METABOLISM; PREGNANCY; TROPHOBLAST;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; ENDOGENOUS RETROVIRUSES; EPIGENESIS, GENETIC; FEMALE; GENE PRODUCTS, ENV; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TROPHOBLASTS;

EID: 84903742322     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990541     Document Type: Article

References (27)

1. Jebbink J, Wolters A, Fernando F, et al. Molecular genetics of preeclampsia and HELLP syndrome - a review. Biochim Biophys Acta 2012; 1822: 1960-9.
2. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008; 359: 262-73.
3. Backes CH, Markham K, Moorehead P, et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy 2011; 214365.
4. Ahn H, Park J, Gilman-Sachs A, et al. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol 2011; 65: 377-94.
5. Warning JC, McCracken SA, Morris JM. A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction 2011; 141: 715-24.
6. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179: 1359-75.
7. Myatt L. Role of placenta in preeclampsia. Endocrine 2002; 19: 103-11.
8. Hertig A, Liere P, Chabbert-Buffet N, et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol 2010; 203: 477 e1-9.
9. MacLennan AH, Sharp F, Shaw-Dunn J. The ultrastructure of human trophoblast in spontaneous and induced hypoxia using a system of organ culture. A comparison with uultrastructural changes in pre-eclampsia and placental insufficiency. J Obstet Gynaecol Br Commonw 1972; 79: 113-21.
10. Langbein M, Strick R, Strissel PL, et al. Impaired cytotrophoblast cell-cell fusion is associated with reduced Syncytin and increased apoptosis in patients with placental dysfunction. Mol Reprod Dev 2008; 75: 175-83.
11. Mi S, Lee X, Li X, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403: 785-9.
12. Huang Q, Li J, Wang F, et al. Syncytin-1 modulates placental trophoblast cell proliferation by promoting G1/S transition. Cell Signal 2013; 25: 1027-35.
13. Lee X, Keith JC, Jr., Stumm N, et al. Downregulation of placental syncytin expression and abnormal protein localization in preeclampsia. Placenta 2001; 22: 808-12.
14. Yu C, Shen K, Lin M, et al. GCMa regulates the syncytin-mediated trophoblastic fusion. J Biol Chem 2002; 277: 50062-8.
15. Matouskova M, Blazkova J, Pajer P, et al. CpG methylation suppresses transcriptional activity of human syncytin-1 in nonplacental tissues. Exp Cell Res 2006; 312: 1011-20.
16. Gao Y, He Z, Wang Z, et al. Increased expression and altered methylation of HERVWE1 in the human placentas of smaller fetuses from monozygotic, dichorionic, discordant twins. PLoS One 2012; 7: e33503.
17. Sargent IL, Germain SJ, Sacks GP, et al. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003; 59: 153-60.
18. Yin LJ, Zhang Y, Lv PP, et al. Insufficient maintenance DNA methylation is associated with abnormal embryonic development. BMC Med 2012; 10: 26.
19. Gimenez J, Montgiraud C, Pichon JP, et al. Custom human endogenous retroviruses dedicated microarray identifies self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. Nucleic Acids Res 2010; 38: 2229-46.
20. Menendez L, Benigno BB, McDonald JF. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 2004; 3: 12.
21. Bjerregaard B, Holck S, Christensen IJ, et al. Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci 2006; 63: 1906-11.
22. Larsen JM, Christensen IJ, Nielsen HJ, et al. Syncytin immunoreactivity in colorectal cancer: potential prognostic impact. Cancer Lett 2009; 280: 44-9.
23. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 339: 1567-70.
24. Chen CP, Chen CY, Yang YC, et al. Decreased placental GCM1 (glial cells missing) gene expression in pre-eclampsia. Placenta 2004; 25: 413-21.
25. Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001; 58: 721-7.
26. El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr 2000; 9: 63-75.
27. Chen CP, Wang KG, Chen CY, et al. Altered placental syncytin and its receptor ASCT2 expression in placental development and pre-eclampsia. Bjog 2006; 113: 152-8.